Table 3.
Survey responses overall and by self‐reported switching and not switching status
| Item | Overall (n = 52) | Switched (n = 40) | Not Switched (n = 12) | P value |
|---|---|---|---|---|
| Biologic Characteristics | ||||
| Mean years receiving infliximab prior to request to switch to infliximab‐dyyb (SD) | 9.3 (5.8) | 9.2 (6.0) | 9.4 (5.4) | 0.630 |
| Satisfaction with current treatment in controlling condition/symptoms (satisfied/very satisfied, no., %) | 44 (84.6) | 32 (80.0) | 12 (100) | 0.092 |
| Knowledge of infliximab‐dyyb prior to request to switch to infliximab‐dyyb (yes, no., %) | 17 (32.7) | 12 (30.0) | 5 (41.7) | 0.496 |
| Biosimilar Concerns | ||||
| Did not know enough about infliximab‐dyyb safety and efficacy prior to switching (yes, no., %) | 20 (38.5) | 15 (37.5) | 5 (41.7) | 0.750 |
| Infliximab‐dyyb may be too expensive (yes, no., %) | 7 (13.5) | 3 (7.5) | 4 (33.3) | 0.022 |
| Infliximab‐dyyb has potential side effects (yes, no., %) | 20 (38.5) | 14 (35.0) | 6 (50.0) | 0.349 |
| Concerned that would lose control over disease with infliximab‐dyyb switching (yes, no., %) | 20 (38.5) | 14 (35.0) | 6 (50.0) | 0.349 |
| Not confident that there is enough information to switch to infliximab‐dyyb (yes, no., %) | n/a | n/a | 7 (58.3) | n/a |
Abbreviation: n/a, not applicable.